



(51) International Patent Classification:

A61K 31/19 (2006.01) *A61P 3/10* (2006.01)
A61P 3/04 (2006.01) *A61P 9/10* (2006.01)
A61P 3/06 (2006.01) *C07C 57/03* (2006.01)

(21) International Application Number:

PCT/IB2011/002925

(22) International Filing Date:

3 November 2011 (03.11.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/410,445 5 November 2010 (05.11.2010) US

(71) Applicant (for all designated States except US):
PRONOVA BIOPHARMA NORGE AS [NO/NO];
P.O. Box 420, N-1327 Lysaker (NO).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HOVLAND, Ragnar** [NO/NO]; Blomsterveien 4 F, N-1450 Nesoddtangen (NO). **SKJÆRET, Tore** [NO/NO]; Roseveien 4 A, N-0585 Oslo (NO). **FRASER, David A.** [GB/NO]; Kirkeveien 81, N-0361 Oslo (NO).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,


AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: METHODS OF TREATMENT USING LIPID COMPOUNDS



(I)

(57) **Abstract:** Methods are disclosed to treat or prevent at least one disease or condition in a subject in need thereof comprising administering a compound of Formula (I): (I) or a pharmaceutically acceptable salt, or ester thereof, wherein R₁ and R₂ are independently chosen from a hydrogen atom or linear, branched, and/or cyclic C₁-C₆ alkyl groups, with the proviso that R₁ and R₂ are not both hydrogen or a pharmaceutically acceptable salt or ester thereof. Such diseases or conditions may relate to coronary heart disease (CHD), for example atherosclerosis; metabolic syndrome/insulin resistance; and/or a dyslipidemic condition such as hypertriglyceridemia (HTG), elevated LDL-cholesterol, elevated total-cholesterol, elevated Apo B and low HDL-cholesterol. The present disclosure further provides for a method of reducing atherosclerosis development. Pharmaceutical compositions comprising a compound of Formula (I) are also disclosed.

